Oura and HP pour $1.8B into health and mobile bets

Oura expands into AI primary care

Oura announced a $625 million cash purchase of Counsel Health, an AI‑native primary‑care startup. The deal marks Oura’s first major move beyond its ring‑based wellness tracker into a service‑oriented health platform.

TechCrunch reported that the acquisition comes just weeks after Oura shelved a planned up‑to‑$2.2 billion IPO, citing “uncertainty in the IPO market.” By buying Counsel, Oura sidesteps a public listing while positioning itself in a segment where AI‑driven triage and virtual visits are gaining investor attention. The company has not disclosed how it will integrate Counsel’s algorithms with its existing hardware, leaving the mechanics of the partnership unclear.

The purchase price suggests Oura sees a sizable addressable market for AI‑first primary care, especially as insurers and employers push for cost‑effective alternatives to in‑person visits. Counsel’s product stack reportedly includes symptom‑checking chatbots and automated referral pathways, but Oura has not revealed whether it will bundle these services with its subscription model or launch a separate offering.

HP doubles down on WebOS with Palm acquisition

HP confirmed a $1.2 billion acquisition of Palm, a move framed as a “double‑down” on the WebOS platform. Senior Vice President of Strategy and Corporate Development Brian Humphries told HN that WebOS is “best‑in‑class” and that HP intends to use its financial strength to take the OS “to the next level.”

The deal includes roughly 1,500 patents that Palm controls, many of which relate to mobile device hardware and software interfaces. Humphries emphasized that HP will keep WebOS “open and friendly to developers,” a stance meant to differentiate the platform from the more closed ecosystems of Apple’s iOS and Google’s Android.

Palm’s CEO Jon Rubinstein is expected to stay on, according to HP’s press release. The acquisition appears to be driven more by software assets than by Palm’s hardware legacy, which suffered lackluster sales before the deal. HP’s existing relationships with Microsoft and Google are noted as less conflicted than those of previous rumored buyer HTC, which faced potential push‑back from both tech giants.

Humphries downplayed patent litigation risk, saying HP “doesn’t think we’re overly concerned” about Apple’s mobile patents despite Apple’s historic scrutiny of Palm. The comment reflects HP’s confidence that the patent portfolio will serve as a defensive moat rather than a source of ongoing legal exposure.

Market context: health‑tech IPO chill and mobile‑OS rivalry

The broader environment for both deals is one of market volatility. In the first half of 2024, several high‑profile health‑tech companies postponed or canceled IPOs as investors grew wary of lofty valuations amid macroeconomic headwinds. Oura’s decision to defer its offering mirrors that trend, and the cash‑rich acquisition route offers an alternative path to growth without the scrutiny of public markets.

On the mobile front, Apple and Google continue to dominate with roughly 70 % combined market share of global smartphone OS installations. WebOS, once a niche player, has not seen a major hardware push since Palm’s decline. HP’s entry revives a platform that could, in theory, offer a third‑party alternative, but the odds of dislodging entrenched ecosystems remain slim.

Industry analysts have long warned that reviving an older OS requires more than patents; it needs a compelling app ecosystem, carrier partnerships, and a clear hardware strategy. HP’s statement that “we’ll compete aggressively” signals ambition, but the company has not outlined a timeline for devices that would run WebOS at scale.

Strategic trade‑offs and open questions

Oura’s diversification into AI primary care raises integration challenges. The company’s core competency lies in hardware sensor data and long‑term health insights, while Counsel’s strength is in rapid, algorithm‑driven clinical decision‑support. Aligning data pipelines, privacy compliance, and user experience across these domains will test Oura’s product roadmap.

The $625 million price tag also reflects a bet that AI‑driven primary care can generate sufficient revenue to offset the cost of acquisition. Without disclosed revenue figures for Counsel, it is unclear whether the purchase is accretive in the short term or a longer‑term play to lock in talent and technology.

HP faces a parallel dilemma. By focusing on WebOS, the company bets that a “best‑in‑class” OS can attract developers despite the dominance of iOS and Android. The 1,500‑patent cache provides a defensive asset, yet patents alone do not guarantee market traction. HP must decide whether to pair WebOS with new hardware, license it to OEMs, or embed it in existing HP products such as laptops and printers.

Both deals leave open the question of execution risk. Will Oura launch a unified health service that leverages its ring data and Counsel’s AI within a single subscription? Will HP secure carrier deals and a developer pipeline sufficient to make WebOS viable beyond niche devices? The answers will shape whether these acquisitions are strategic footholds or costly diversions.

What to watch

In the next six months, track Oura’s product announcements for any integrated primary‑care offering, as well as regulatory filings that could reveal how the company plans to handle patient data. For HP, monitor developer conference sessions for WebOS SDK releases, carrier partnership announcements, and any prototype hardware that showcases the OS in a consumer device. The success of these signals will indicate whether the $1.8 billion combined spend translates into sustainable market positions or remains a high‑risk expansion.

Updates

• 2026-11-11 — Oura is acquiring medical AI chatbot startup Counsel Health (source)